Abstract Abstract In this research, berberine (BB), and its effect on the biological performance of DBTRG brain cancer cells and normal endothelial cells (EC) was investigated. Firstly, the DBTRG cancer cell and EC cell were cultured with different concentrations of BB (0.5, 1, 5 and 10 μg/ml), and it was confirmed that BB significantly reduced the proliferation of DBTRG cancer cells. However, there is no significant toxic effect on EC cells. The results of cell cycle analysis confirmed that BB significantly induced DBTRG cancer cell undergo apoptotic effect in a dose dependent manner. The assessment of cell migration behavior showed that BB significantly inhibited cell migration in DBTRG cancer cell, but not in BAEC as well as attenuated the matrix metalloproteinase 2/9 (MMP2/9) in a dose dependent manner. Furthermore, the reactive oxygen species (ROS) generation capacity among DBTRG cancer cell, EC cell and macrophages (Raw 264.7). It was demonstrated that BB was prominently decreased the ROS generation of DBTRG instead of EC or Raw264.7 cell. Moreover, the pro-inflammatory cytokines of TNF-α, IL-1β and IL-6 were significantly inhibited by BB in a dose dependent manner of DBTRG brain cancer cell. As mentioned above, it was demonstrated that bioactive BB molecules is potential for anti-brain cancer drugs may via anti-immune response and anti-oxidative generation capacity for brain cancer therapy. BB biomolecules may target for DBTRG cell which cannot cause inevitable toxic damage to the normal EC cell. Altogether, the promising findings of BB biomolecule on DBTRG cancer cell suggest that BB may be a good candidate of anticancer drug or adjuvant for the treatment of human brain cancer. Key words: berberine, DBTRG brain cancer, anti-immune response, anti-oxidative generation
Read full abstract